Technology

The Technology

Bacteriophages are natural enemies of bacteria and, when properly selected, can be used to prevent and control bacterial populations, including bacteria resistant to antibiotics. Phages are specific to a group of bacteria without affecting the normal microbiota of animals. They are more efficient compared to antibiotics, as they only multiply when their specific host is present. After infection and when the host concentration has decreased, the phage population also decreases. Other advantages of phage therapy include modulation of the host’s microbiota with the potential to improve their health, as well as immunomodulatory activity which helps to resolve infection. SalmoFree®, our first product targeting Salmonella in the poultry industry, has demonstrated its potential to improve agricultural production systems and promote the adoption of cleaner industrial processes, therefore, its integration into the market will reduce the use of antibiotics in this value chain. This, in turn, will significantly reduce environmental residues from recirculating antibiotics endangering human health, solving not only a food safety problem but also an urgent public health need.

Advantages and Benefits

Phages are natural enemies of the bacteria.
With our optimal phage selection, our products overcome bacterial resistance, improve environment, human and animal health, and promote self sustainable industries.

Phase 1

A strategy that has recently attracted a lot of interest is phage therapy, which consists of the use of bacteriophages (or more commonly called phages) for the treatment of bacterial infections or the control of bacteria that cause different problems in the industry in general.

Phase 2

Phages specifically infect bacterial cells, hijack their molecular machinery and use it to carry out their propagation, resulting in bacterial cell lysis and the release of phage progeny.

Phase 3

They are highly specific and they does not favor the generation of extensive resistance.

Phase 4

Its application in humans or other organisms is safe.

Phase 5

Phages are easy to isolate and propagate in the laboratory.

Phase 6

Its scale production would have a cost significantly lower than that associated with the production of new antibiotics.

Phase 7

Phages have the ability to spread at the site of infection, increasing their dose in-situ.

Phase 8

Phages have the ability to co-evolve with the bacteria they infect, potentially allowing them to counteract the generation of resistance by them.

Are you interested in what we do?

Let’s talk! Contact us and we will be in touch ass soon as possible.